Drug Trial Radar · NCT06311214
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Mar 18, 2025
Primary completion
Mar 31, 2028
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Mar 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II ADC MATCH screening and multi-sub-study treatment trial is evaluating whether biomarker-directed treatment with one of three antibody-drug conjugates (ADCs) (sacituzumab govitecan, enfortumab vedotin, and trastuzumab deruxtecan) works in treating patients with solid tumor cancers that have high expression of the Trop-2, nectin-4, or HER2 proteins and that may have spread from where they first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced) or to other places in the body (metastatic). Precision medicine is a form of medicine that uses information about a person's genes, proteins, and environment to prevent, diagnose, or treat disease in a way that is tailored to the patient. ADCs such as sacituzumab govitecan, enfortumab vedotin, and trastuzumab deruxtecan are monoclonal antibodies attached to biologically active drugs and are a form of targeted therapy. Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a drug called govitecan. Sacituzumab attaches to a protein called Trop-2 on the surface of tumor cells and delivers govitecan to kill them. Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of tumor cells. Enfortumab attaches to a protein called nectin-4 on tumor cells in a targeted way and delivers vedotin to kill them. Trastuzumab deruxtecan is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive tumor cells in a targeted way and delivers deruxtecan to kill them. Personalized treatment with sacituzumab govitecan, enfortumab vedotin, or trastuzumab deruxtecan may be an effective treatment option for patients with advanced or metastatic solid tumors that screen positive for high expression of Trop-2, nectin-4, or HER2, respectively.
Conditions
- Advanced Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm
Interventions
Biopsy ProcedureProcedure
Undergo biopsy
Biospecimen CollectionProcedure
Undergo collection of blood samples
Computed TomographyProcedure
Undergo CT
Echocardiography TestProcedure
Undergo ECHO
Electronic Health Record ReviewOther
Undergo review of SOC RNA testing results
Enfortumab VedotinDrug
Given IV
Immunohistochemistry Staining MethodOther
Undergo IHC assay
Magnetic Resonance ImagingProcedure
Undergo MRI
Multigated Acquisition ScanProcedure
Undergo MUGA
Sacituzumab GovitecanBiological
Given IV
Trastuzumab DeruxtecanBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of high protein expression in patients with high ribonucleic acid (RNA) expression of each antibody-drug conjugate target (screening protocol)Time frame: Up to completion of screening period
- Objective response rate (treatment cohorts)Time frame: Up to 3 years
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
UC San Diego Health System - Encinitas
Encinitas, California · Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
City of Hope at Irvine Lennar
Irvine, California · Recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
UC San Diego Medical Center - Hillcrest
San Diego, California · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Smilow Cancer Hospital Care Center-Trumbull
Trumbull, Connecticut · Recruiting
UF Health Cancer Institute - Gainesville
Gainesville, Florida · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
University of Kentucky/Markey Cancer Center
Lexington, Kentucky · Recruiting
Ochsner Medical Center Jefferson
New Orleans, Louisiana · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri · Recruiting
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Siteman Cancer Center-South County
St Louis, Missouri · Recruiting
Siteman Cancer Center at Christian Hospital
St Louis, Missouri · Recruiting
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York · Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma · Recruiting
Vanderbilt Breast Center at One Hundred Oaks
Nashville, Tennessee · Recruiting
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee · Recruiting
UT MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Virginia Cancer Center
Charlottesville, Virginia · Recruiting
VCU Massey Comprehensive Cancer Center
Richmond, Virginia · Recruiting
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin · Recruiting
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.